Scholarlink

<p>Casein kinase 1δ (CK1δ, encoded by <i>casein kinase 1 delta</i>) (CSNK1D) is a serine/threonine protein kinase closely associated with cancer development. However, the biological functions of CSNK1D in head and neck squamous cell carcinoma (HNSCC) remain unclear. This study identifies CSNK1D as a previously unrecognized yet crucial regulator in the progression of HNSCC. CSNK1D expression levels were upregulated in tumor tissues and the up-regulation was positively correlated with poor survival in patients with HNSCC. Moreover, CSNK1D selectively bound SHH and PTCH1, and regulated the stability of the CSNK1D-SHH-PTCH1 complex to control the GLI1-BCL2 axis, leading to the downstream activation of the hedgehog pathway. SB-203580 could target and inhibit CSNK1D, offering new perspectives for the clinical treatment of HNSCC. Overall, CSNK1D is underscored as a vital oncogenic driver and promising therapeutic target for HNSCC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CSNK1D inhibition suppresses head and neck squamous cell carcinoma progression through SHH and PTCH1 pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Li Yang,
  • Xiang Li,
  • Yun Zhu,
  • Yu Zhang,
  • Zheqi Liu,
  • Chengzhong Lin,
  • Canhua Jiang,
  • Yu-Xiong Su,
  • Tong Ji,
  • Yang Wang,
  • Jun Gao,
  • Jinhai Ye

摘要

Casein kinase 1δ (CK1δ, encoded by casein kinase 1 delta) (CSNK1D) is a serine/threonine protein kinase closely associated with cancer development. However, the biological functions of CSNK1D in head and neck squamous cell carcinoma (HNSCC) remain unclear. This study identifies CSNK1D as a previously unrecognized yet crucial regulator in the progression of HNSCC. CSNK1D expression levels were upregulated in tumor tissues and the up-regulation was positively correlated with poor survival in patients with HNSCC. Moreover, CSNK1D selectively bound SHH and PTCH1, and regulated the stability of the CSNK1D-SHH-PTCH1 complex to control the GLI1-BCL2 axis, leading to the downstream activation of the hedgehog pathway. SB-203580 could target and inhibit CSNK1D, offering new perspectives for the clinical treatment of HNSCC. Overall, CSNK1D is underscored as a vital oncogenic driver and promising therapeutic target for HNSCC.